We Present the Scientific Evidence for EECP Transparently
This page is not promotional material. It aims to convey the published peer-reviewed medical literature on EECP (Enhanced External Counterpulsation) without concealing the type of evidence or its limitations. For each study below, the type (randomized controlled trial, systematic review/meta-analysis, or observational registry data), author, journal, year, and a link to the original source are indicated. You can also find a shorter summary of this topic in our EECP Scientific Research article.
Studies Examining EECP With Sham Controls
MUST-EECP (Multicenter Study of Enhanced External Counterpulsation)
A multicenter study in which 139 patients with chronic angina were randomized to active EECP (n=72) or a sham/placebo device (n=67). The active treatment group showed a significant reduction in angina attack frequency and exercise-induced ischemia duration compared to the sham group. Improvements in quality-of-life measures were larger, but reached statistical significance in only 3 of 9 parameters. The subsequent Cochrane review highlighted this study's methodological limitations (low response rate, exclusion of the most severe CCS Class IV patients).
View on JACC (DOI)PEECH (Prospective Evaluation of EECP in Congestive Heart Failure)
A randomized trial evaluating the effect of EECP on exercise tolerance in 187 heart failure patients with left ventricular ejection fraction ≤35%. The proportion of patients with a ≥60-second increase in exercise duration was higher in the EECP group than in the control group (35% vs. 25%), and improvement was observed in the Minnesota Living with Heart Failure score. No significant difference was found between groups in peak VO2 (a measure of exercise capacity) across the full patient group, indicating that EECP's effect can vary depending on the parameter measured.
View on JACC (DOI)Analyses Combining Multiple Studies
Does EECP Reduce Symptoms of Chronic and Refractory Angina?
After screening 318 sources, only 1 eligible randomized trial (MUST-EECP) could be identified. The Cochrane authors stated that the current evidence is insufficient to draw a robust conclusion about the efficacy and safety of EECP; this was attributed to limitations in study quality and the inability to generalize the results to the most severely symptomatic patient group. This is the most notable limiting assessment in the EECP literature, and it is not hidden on this page.
View on Cochrane LibraryEECP Efficacy by CCS Class in Refractory Angina
An updated meta-analysis pooling the change in Canadian Cardiovascular Society (CCS) angina class after EECP in patients with chronic refractory angina. The included studies reported an average improvement in CCS class; however, the authors note that most of the analyzed studies were uncontrolled/single-arm in design, which limits the strength of the evidence.
View on PubMedThe Effect of EECP on Endothelial Function
This meta-analysis, which pools randomized controlled trials, shows that EECP may be associated with improvement in markers of endothelial function such as flow-mediated dilation (FMD). This is indirect (surrogate) evidence for EECP's proposed microcirculation/vessel-wall mechanism; it is not a direct clinical outcome measure (death, MI, hospitalization), and this distinction is important.
View on PubMedDoes EECP Significantly Affect Myocardial Perfusion?
A systematic review pooling imaging studies (SPECT/perfusion tests); while improvement in myocardial perfusion has been reported in some patients after EECP, the review highlights considerable heterogeneity among the studies in terms of methodology and patient selection.
View on PLOS ONEReal-World Patient Registries
Registry studies provide real-world data from thousands of patients, but because they do not include a control group, they do not prove causation; results may also be influenced by factors other than the treatment itself (natural course over time, concurrent therapies, etc.).
International EECP Patient Registry (IEPR) — Long-Term Follow-Up in Refractory Angina
Long-term follow-up data from a multicenter registry of patients who received EECP for chronic refractory angina. The registry reports that a significant proportion of patients experienced improvement in angina class and a reduction in angina attack frequency after treatment. This is not a randomized trial; there is no control group, and the results should be interpreted accordingly.
View on PubMedHow Is EECP Positioned in Guidelines and by Regulatory Authorities?
ACC/AHA Stable Ischemic Heart Disease Guideline
In the joint guideline update from the American College of Cardiology and the American Heart Association, EECP is listed as an option that may be considered (Class IIb, Level of Evidence B) for stable ischemic heart disease patients with refractory angina despite optimal medical therapy. In guideline terminology, Class IIb means the benefit is less well supported by evidence/opinion; it does not mean a first-line or strongly recommended treatment.
View ACC.org Guideline SummaryUS FDA Device Classification
The US Food and Drug Administration (FDA) has classified external counterpulsation (ECP) devices used for the refractory angina indication as Class II medical devices and has subjected them to the 510(k) clearance process. This page and other pages on this site deliberately avoid the phrase "FDA approved," because that term is technically used for Class III devices that go through the PMA (Premarket Approval) process. The correct term for EECP devices is an FDA-cleared Class II device.
View Regulatory SourceAn Honest Assessment of the Evidence
Common Questions About Clinical Evidence
Is there scientific evidence for EECP?
Yes; there is a randomized controlled trial (MUST-EECP), observational registry data (IEPR), and various meta-analyses. However, the Cochrane systematic review states that this evidence base is not yet sufficient to conclusively prove efficacy. This is not an absence of evidence, but a limited and evolving evidence base.
What exactly did the MUST-EECP study show?
In this randomized trial of 139 patients, the group receiving active EECP showed a significant reduction in angina attack frequency compared to the sham group. However, the study's sample size is small, and the most severely symptomatic patients were not included in the trial.
Is EECP an FDA-approved treatment?
No, that is not the correct term. EECP devices have been classified by the FDA as Class II medical devices and cleared for marketing through the 510(k) process. This is not the same regulatory category as treatments that go through the PMA (Premarket Approval) process; for this reason, we do not use the phrase "FDA approved" on our site.
How strong is the level of evidence, and what should I do when deciding on treatment?
The current evidence consists of a limited number of randomized trials, several meta-analyses, and large-scale but uncontrolled registry data. Whether EECP is appropriate for you should be decided by a cardiology team, taking into account your current test results and overall health status.
Let's Assess Your Situation After Reviewing the Evidence
You can find out whether EECP is a meaningful option for your clinical condition by getting a free preliminary assessment from our cardiology team.